UPB · Upstream Bio, Inc.
$6.41
+0.00% last session
End-of-day data · updated 2026-07-28
Market cap
$0B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-2.2
Dividend yield
—
Beta
—
Avg volume
1M
Employees
0K
2D change
—
5D change
0.00%
10D change
-8.70%
30D change
-5.19%
60D change
-23.44%
MTD change
-12.09%
YTD change
-76.43%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — UPB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-12
Latest call per bank · past 12 months
JP Morgan
Neutral$8.00
+24.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-12 | JP Morgan | Downgrade | Overweight → Neutral | $35.00 → $8.00 |
| 2026-06-03 | HC Wainwright & Co. | Initiates | Buy | $0.00 → $36.00 |
| 2026-05-14 | Mizuho | Maintains | Outperform | $51.00 → $50.00 |
| 2026-03-27 | Evercore ISI Group | Downgrade | Outperform → In-Line | $40.00 → $15.00 |
| 2025-12-18 | Mizuho | Initiates | Outperform | $0.00 → $51.00 |
| 2025-12-02 | LifeSci Capital | Initiates | Outperform | $0.00 → $43.00 |
| 2025-11-18 | Evercore ISI Group | Initiates | Outperform | $0.00 → $40.00 |
| 2025-10-14 | Truist Securities | Initiates | Buy | $0.00 → $47.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.5% below the 50-day MA ($7.23).
- Price vs 200-day MA: Trading 60.6% below the 200-day MA ($16.23).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.09) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($5.92).
UPB Price Chart
Loading chart for UPB…
Fundamentals
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.